Monash IVF Group Ltd
F:MIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Monash IVF Group Ltd
F:MIS
|
AU |
|
F
|
Fervo Energy Co
NASDAQ:FRVO
|
US |
|
Allcargo Logistics Ltd
NSE:ALLCARGO
|
IN |
|
Omega Diagnostics Group PLC
F:RVKA
|
UK |
Monash IVF Group Ltd
Monash IVF Group Ltd is a fertility care company that helps people trying to have children. It runs clinics that offer in vitro fertilization, fertility testing, egg freezing, donor services, and related treatments. The company also works with doctors and specialists who refer patients for fertility care and genetic testing. Its main customers are individuals and couples seeking fertility treatment, along with doctors who send patients into its clinics. Monash IVF makes money by charging for consultations, procedures, laboratory work, storage services, and genetics testing. Some of these services may also be partly supported through public health or private insurance systems, depending on the treatment and location. What makes the business different is that it sits in a highly specialized part of healthcare where medical expertise, laboratory capability, and patient support all matter at the same time. It is not a general hospital or a drug maker; it is a focused fertility services provider that combines clinical care with embryo and genetic laboratory work.
Monash IVF Group Ltd is a fertility care company that helps people trying to have children. It runs clinics that offer in vitro fertilization, fertility testing, egg freezing, donor services, and related treatments. The company also works with doctors and specialists who refer patients for fertility care and genetic testing.
Its main customers are individuals and couples seeking fertility treatment, along with doctors who send patients into its clinics. Monash IVF makes money by charging for consultations, procedures, laboratory work, storage services, and genetics testing. Some of these services may also be partly supported through public health or private insurance systems, depending on the treatment and location.
What makes the business different is that it sits in a highly specialized part of healthcare where medical expertise, laboratory capability, and patient support all matter at the same time. It is not a general hospital or a drug maker; it is a focused fertility services provider that combines clinical care with embryo and genetic laboratory work.
Earnings: Underlying NPAT of $10.4 million for H1 FY'26, delivered at the upper end of the AGM guidance range and underlying EBITDA of $30.2 million (22% margin).
Revenue: Group revenue was $137.9 million, down 1.8% vs prior comparable period; group stimulated cycles fell to 5,862, down 9.9%.
Guidance: FY'26 underlying NPAT guidance reiterated at $20 million and an interim fully franked dividend of $0.012 per share declared.
Margins & costs: EBITDA margin declined 3.5 percentage points, attributed to weaker volumes, legal/compliance costs, wage inflation and investment in clinical governance; management is targeting margin recovery through revenue and cost initiatives.
Clinical performance: Pregnancy rate per embryo transferred improved to 40.7% (up 0.6 percentage points year-on-year) and 49% for women under 35, which management highlights as a competitive strength.
Genetics & innovation: Genetics volumes and conversion indicators are strong (PGT-A up 31%, PGTM up 26%, PGTM cycle conversion up 25%); wearable hormone and other R&D programs progressing.
Regional performance: Asia business growing (Singapore stimulated cycles +6.4%, Johor Bahru +26%, KL revenue per cycle +7%); domestic market share declined to 19% (down 2.5ppt) with NSW and Victoria soft.
Leadership & strategy: New CEO outlined a focus on stabilizing operations, rightsizing costs, enhancing patient experience, strengthening medical leadership and completing final major clinic CapEx (Brisbane opening Q4 FY'26).
